eJHaem
(Feb 2023)
Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy
Thi H. O. Nguyen,
Chhay Lim,
Masa Lasica,
Ashley Whitechurch,
Surekha Tennakoon,
Natalie R. Saunders,
Lilith F. Allen,
Louise C. Rowntree,
Brendon Y. Chua,
Lukasz Kedzierski,
Hyon‐Xhi Tan,
Adam K. Wheatley,
Stephen J. Kent,
Theo Karapanagiotidis,
Suellen Nicholson,
Deborah A. Williamson,
Monica A. Slavin,
Constantine S. Tam,
Katherine Kedzierska,
Benjamin W. Teh
Affiliations
Thi H. O. Nguyen
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Chhay Lim
Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia
Masa Lasica
Department of Haematology St Vincent's Hospital Fitzroy Victoria Australia
Ashley Whitechurch
Department of Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia
Surekha Tennakoon
Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia
Natalie R. Saunders
Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia
Lilith F. Allen
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Louise C. Rowntree
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Brendon Y. Chua
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Lukasz Kedzierski
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Hyon‐Xhi Tan
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Adam K. Wheatley
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Stephen J. Kent
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Theo Karapanagiotidis
Victorian Infectious Diseases Reference Laboratory The Peter Doherty Institute for Infection and Immunity Melbourne Victoria Australia
Suellen Nicholson
Victorian Infectious Diseases Reference Laboratory The Peter Doherty Institute for Infection and Immunity Melbourne Victoria Australia
Deborah A. Williamson
Victorian Infectious Diseases Reference Laboratory The Peter Doherty Institute for Infection and Immunity Melbourne Victoria Australia
Monica A. Slavin
Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia
Constantine S. Tam
Department of Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia
Katherine Kedzierska
Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia
Benjamin W. Teh
Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia
DOI
https://doi.org/10.1002/jha2.639
Journal volume & issue
Vol. 4,
no. 1
Abstract
Read online
Abstract Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 vaccination. Overall, 45 patients (median 72 years old) were recruited; the majority were male (71%), had CLL (76%) and were on zanubrutinib (78%). Seroconversion rates were 65% and 77% following two and three doses, respectively. CD4+ and CD8+ T‐cell response rates increased with third dose. In zanubrutinib‐treated patients, 86% developed either a humoral or cellular response. Patients on zanubrutinib developed substantial immune responses following two COVID‐19 vaccine doses, which further improved following a third dose.
Keywords
WeChat QR code
Close
